Denosumab For The Treatment Of Bisphosphonate-Refractory Hypercalcemia Of Malignancy - A Case Report | Zendy

Vishal Ramteke | Zendy; Sudhir Ranjan Dash | Zendy; Shubhadeep Bose | Zendy; Ritu Jain | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Denosumab For The Treatment Of Bisphosphonate-Refractory Hypercalcemia Of Malignancy - A Case Report

Author(s) -

Vishal Ramteke,

Sudhir Ranjan Dash,

Shubhadeep Bose,

Ritu Jain

Publication year - 2015

Publication title -

j med sci

Language(s) - English

Resource type - Journals

eISSN - 2582-063X

pISSN - 0972-110X

DOI - 10.33883/jms.v18i2.266

Subject(s) - medicine , denosumab , bisphosphonate , malignancy , refractory (planetary science) , bone density conservation agents , osteoclast , bone resorption , rankl , osteoporosis , oncology , surgery , bone density , receptor , physics , activator (genetics) , astrobiology

Hypercalcemia of malignancy caused primarily by tumor-induced bone resorption may lead to renal failure, coma, and death. Patients treated with routine intravenous bisphosphonates may not respond or may relapse on therapy. Denosumab, a monoclonal human antibody which binds to RANKL, inhibits the osteoclast mediated bone resorption and hypercalcemia. We report a case of hypercalcemia in patient with metastatic carcinoma breast refractory to bisphosphonate therapy responding to denosumab and to the best of our knowledge is the first reported case in Indian literature. JMS 2015; 8(2):153-155

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research